GlaxoSmithKline Debt to Equity Ratio 2006-2018 | GSK

Current and historical debt to equity ratio values for GlaxoSmithKline (GSK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. GlaxoSmithKline debt/equity for the three months ending September 30, 2018 was 6.66.
GlaxoSmithKline Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $32.33B $4.85B 6.66
2018-06-30 $33.47B $4.11B 8.14
2018-03-31 $19.50B $5.00B 3.90
2017-12-31 $18.38B $4.50B 4.09
2017-09-30 $18.71B $6.32B 2.96
2017-06-30 $15.68B $5.66B 2.77
2017-03-31 $18.09B $6.93B 2.61
2016-12-31 $19.87B $6.73B 2.95
2016-09-30 $20.23B $5.25B 3.85
2016-06-30 $21.66B $6.06B 3.57
2016-03-31 $22.57B $9.37B 2.41
2015-12-31 $23.43B $13.57B 1.73
2015-09-30 $23.43B $14.47B 1.62
2015-06-30 $22.51B $16.16B 1.39
2015-03-31 $23.08B $17.30B 1.33
2014-12-31 $26.11B $8.14B 3.21
2014-09-30 $22.76B $9.61B 2.37
2014-06-30 $24.42B $11.51B 2.12
2014-03-31 $25.46B $12.30B 2.07
2013-12-31 $24.19B $12.22B 1.98
2013-09-30 $24.27B $10.54B 2.30
2013-06-30 $25.04B $11.17B 2.24
2013-03-31 $26.88B $11.84B 2.27
2012-12-31 $23.26B $10.70B 2.17
2012-09-30 $21.06B $11.10B 1.90
2012-06-30 $21.50B $12.35B 1.74
2012-03-31 $18.84B $15.04B 1.25
2011-12-31 $19.58B $14.16B 1.38
2011-09-30 $22.91B $13.27B 1.73
2011-06-30 $23.22B $15.40B 1.51
2011-03-31 $23.74B $15.83B 1.50
2010-12-31 $22.90B $15.07B 1.52
2010-09-30 $23.02B $16.45B 1.40
2010-06-30 $22.15B $14.24B 1.56
2010-03-31 $23.77B $17.84B 1.33
2009-12-31 $23.15B $15.67B 1.48
2009-09-30 $24.68B $15.23B 1.62
2009-06-30 $20.23B $11.95B 1.69
2009-03-31 $21.72B $11.59B 1.87
2008-12-31 $28.25B $15.43B 1.83
2008-09-30 $24.28B $14.20B 1.71
2008-06-30 $24.78B $14.67B 1.69
2008-03-31 $16.15B $18.33B 0.88
2007-12-31 $14.14B $19.22B 0.74
2007-09-30 $9.87B $19.97B 0.49
2007-06-30 $9.97B $21.43B 0.47
2007-03-31 $6.27B $13.02B 0.48
2006-12-31 $8.80B $17.30B 0.51
2006-09-30 $9.10B $17.18B 0.53
2006-06-30 $8.91B $16.11B 0.55
2006-03-31 $9.27B $15.46B 0.60
2005-12-31 $9.60B $13.31B 0.72
2005-09-30 $9.22B $12.56B 0.73
2005-06-30 $9.34B $11.75B 0.80
2005-03-31 $7.71B $10.49B 0.74
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $102.669B $38.892B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
Bristol-Myers Squibb (BMY) United States $85.837B 14.14